thalidomide has been researched along with sq-23377 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, J; Chao, NJ; Chen, Y; Fernandez, LP; Schlegel, PG | 1 |
| Chen, RS; Haley, M; Hughes, CC; Muller, GW; Naziruddin, SD; Parton, A; Payvandi, F; Schafer, PH; Stirling, DI; Wu, L | 1 |
2 other study(ies) available for thalidomide and sq-23377
| Article | Year |
|---|---|
Does thalidomide affect IL-2 response and production?
Topics: beta-Galactosidase; Cells, Cultured; Clone Cells; Dose-Response Relationship, Drug; Enhancer Elements, Genetic; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-2; Ionomycin; Kinetics; Leukemia; Lymphocyte Activation; Lymphocytes; Tetradecanoylphorbol Acetate; Thalidomide; Transfection; Tumor Cells, Cultured | 1995 |
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.
Topics: Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression Regulation; Humans; Immunologic Factors; Interleukin-2; Ionomycin; Ionophores; Isoenzymes; K562 Cells; Killer Cells, Natural; Lymphocyte Activation; Protein Kinase C; Protein Kinase C-theta; T-Lymphocytes; Tetradecanoylphorbol Acetate; Thalidomide; Transcription Factors | 2005 |